Is MRTX a buy or a sell?
The Discounted Cash Flow (DCF) valuation of Mirati Therapeutics Inc (MRTX) is (1,501.94) USD. With the latest stock price at 58.70 USD, the upside of Mirati Therapeutics Inc based on DCF is -2658.7%. This means that MRTX is a sell according to the DCF valuation model.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.7% - 7.9% | 6.8% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (5,706.55) - (877.57) | (1,501.94) |
| Upside | -9821.6% - -1595.0% | -2658.7% |